Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function

Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function

<strong>Background</strong> The capsular group B meningococcal vaccine (4CMenB) is recommended for children with complement deficiencies, asplenia and splenic dysfunction, however, data on the immunogenicity of 4CMenB in these ‘at-risk’ children are missing. <strong>Methods</st...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Martinón-Torres, FL, Bernatowska, E, Shcherbina, A, Esposito, S, Szenborn, L, Marti, MC, Hughes, S, Faust, SN, Yu, LM, D’Agostino, D, Calabresi, M, Toneatto, D, Snape, MD
التنسيق:	Journal article
منشور في:	American Academy of Pediatrics 2018

مواد مشابهة

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
حسب: Snape, MD, وآخرون
منشور في: (2010)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
حسب: Snape, MD, وآخرون
منشور في: (2013)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
حسب: Snape, M, وآخرون
منشور في: (2013)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
حسب: Read, R, وآخرون
منشور في: (2014)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial
حسب: Read, R, وآخرون
منشور في: (2014)

Meningitis and meningococcal septicaemia.
حسب: Pollard, A, وآخرون
منشور في: (1998)

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
حسب: Gossger, N, وآخرون
منشور في: (2012)

Meningitis and meningococcal septicaemia - Extended review
حسب: Pollard, A, وآخرون
منشور في: (1998)

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
حسب: Snape, MD, وآخرون
منشور في: (2013)

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial
حسب: Snape, MD, وآخرون
منشور في: (2013)

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
حسب: Snape, MD, وآخرون
منشور في: (2008)

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
حسب: Perrett, K, وآخرون
منشور في: (2009)

Meningococcal meningitis presenting postinfant group B meningococcal immunisation
حسب: So, N, وآخرون
منشور في: (2018)

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents
حسب: Timo Vesikari, وآخرون
منشور في: (2021-11-01)

Emergency management of meningococcal disease: eight years on.
حسب: Pollard, A, وآخرون
منشور في: (2007)

Emerging experience with meningococcal serogroup B protein vaccines
حسب: Daniela Toneatto, وآخرون
منشور في: (2017-05-01)

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
حسب: Sadarangani, M, وآخرون
منشور في: (2017)

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
حسب: Pace, D, وآخرون
منشور في: (2015)

Meningococcal polysaccharide-protein conjugate vaccines.
حسب: Snape, MD, وآخرون
منشور في: (2005)

Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.
حسب: Ramasamy, M, وآخرون
منشور في: (2014)

Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis.
حسب: Faust, SN, وآخرون
منشور في: (2008)

Terminal Complement Pathway Deficiency in an Adult Patient with Meningococcal Sepsis
حسب: F. Staels, وآخرون
منشور في: (2022-01-01)

Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants
حسب: Valente Pinto, M, وآخرون
منشور في: (2020)

A Mouse Immunogenicity Model for the Evaluation of Meningococcal Conjugate Vaccines
حسب: Arun B. Arunachalam, وآخرون
منشور في: (2022-01-01)

A randomized trial assessing the immunogenicity and reactogenicity of two hexavalent infant vaccines concomitantly administered with group b meningococcal vaccine
حسب: Rajan, M, وآخرون
منشور في: (2022)

Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
حسب: McQuaid, F, وآخرون
منشور في: (2014)

Susceptibility to invasive meningococcal disease: polymorphism of complement system genes and Neisseria meningitidis factor H binding protein.
حسب: Declan T Bradley, وآخرون
منشور في: (2015-01-01)

Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study
حسب: Nan-Chang Chiu, وآخرون
منشور في: (2018-05-01)

Do we really want to end meningococcal disease (and current inequity)?
حسب: Federico Martinón-Torres
منشور في: (2024-05-01)

Control of invasive meningococcal disease: is it achievable?
حسب: Marshall, H, وآخرون
منشور في: (2016)

Will booster doses be required for serogroup B meningococcal vaccine?
حسب: McQuaid, F, وآخرون
منشور في: (2014)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
حسب: Samba O. Sow, وآخرون
منشور في: (2023-08-01)

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
حسب: Davis, K, وآخرون
منشور في: (2021)

Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants.
حسب: Collins, C, وآخرون
منشور في: (2005)

Safety and Immunogenicity of a Tetravalent Polysaccharide Vaccine Against Meningococcal Disease
حسب: Pei-Lan Shao, وآخرون
منشور في: (2009-07-01)

The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.
حسب: Lisa A Lewis, وآخرون
منشور في: (2010-07-01)

The challenge of post-implementation surveillance for novel meningococcal vaccines.
حسب: Snape, MD, وآخرون
منشور في: (2012)

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
حسب: Snape, M, وآخرون
منشور في: (2015)

Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
حسب: Rivero-Calle I, وآخرون
منشور في: (2019-10-01)

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
حسب: McQuaid, F, وآخرون
منشور في: (2015)